Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

302.96
+0.22000.07%
Post-market: 302.960.00000.00%19:30 EDT
Volume:179.23K
Turnover:54.44M
Market Cap:6.04B
PE:31.20
High:307.63
Open:307.55
Low:301.32
Close:302.74
52wk High:326.63
52wk Low:175.89
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.48
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:6.24
PE(LYR):49.42

Loading ...

StoneX's New Best Ideas List: 5 Stocks In, 3 Stocks Out

Analyst Calls
·
Oct 02

Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target

MT Newswires Live
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Sep 25

Ligand initiated with an Overweight at Barclays

TIPRANKS
·
Sep 25

Ligand Pharmaceuticals Price Target Maintained with a $358.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 25

Wainwright sees upside in Ligand after new CAR-T investment in AvenCell

TIPRANKS
·
Sep 24

Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell

MT Newswires Live
·
Sep 24

Ligand and Avencell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

THOMSON REUTERS
·
Sep 24

Ligand Pharmaceuticals Incorporated - Commits up to $6 Mln in Series C Financing

THOMSON REUTERS
·
Sep 24

Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

Dow Jones
·
Sep 24

Ligand Pharmaceuticals is Maintained at Buy by Citigroup

Dow Jones
·
Sep 23

Ligand Pharmaceuticals Incorporated : Citigroup Raises Target Price to $397 from $390

THOMSON REUTERS
·
Sep 23

Ligand price target raised to $397 from $390 at Citi

TIPRANKS
·
Sep 23

Ligand Pharmaceuticals Joins Signet-Led Financing Round in Primrose Bio

Reuters
·
Sep 22

Sydnexis : Agreement Includes $23 Mln Upfront Payment

THOMSON REUTERS
·
Sep 22

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea

THOMSON REUTERS
·
Sep 22

Press Release: Primrose Bio(R) Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Dow Jones
·
Sep 22

Ligand Buys Ryjunea Royalty, Milestone Interest from Sydnexis for $23 Million

Reuters
·
Sep 22

Ligand Pharmaceuticals Incorporated - to Receive Tiered Royalty on Ryjunea Net Sales in Emea

THOMSON REUTERS
·
Sep 22

Ligand Pharmaceuticals Incorporated - Buys Rights to Royalty and Milestone Payments on Ryjunea in Emea

THOMSON REUTERS
·
Sep 22